The Blue Cross Blue Shield Federal Employee Program criteria for Saxenda and Wegovy, policy 5.99.030, effective July 1, 2026, require prior participation in a comprehensive weight management program, and at renewal that an adult has lost at least 5 percent of baseline body weight OR the patient has continued to maintain their initial 5 percent weight loss. That is one of the few places in these documents where maintaining rather than losing is written down as a reason to keep paying
Nevertheless, given the close association of obesity and type 2 diabetes with MASLD, several other drugs that are approved for treatment of obesity and type 2 diabetes are being tested for treatment of the progressive form of MASLD, or metabolic dysfunction-associated steatohepatitis
Before starting any skincare regimen, you should speak with a professional
Common and Serious Side Effects Some side effects are fairly common, like nausea, vomiting, diarrhea, and stomach discomfort